48 results about "Posttraumatic stress disorders" patented technology

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.

The invention belongs to the field of medicinal chemical engineering, and relates to application of 2-arylimidazo[1,2-alpha]pyridine-3-acetamide derivatives to prepare medicines for controlling PTSD (posttraumatic stress disorder). Specifically, the invention relates to application of a compound shown as a formula I and pharmaceutically salts thereof to prepare medicines for controlling and/or treating and/or auxiliarily treating PTSD, wherein the compound and the pharmaceutically salts thereof are used as TSPO (translocator protein) ligands. The TSPO ligands such as the compounds shown as the formula I and the pharmaceutically salts are capable of effectively preventing and/or treating and/or auxiliarily treating PTSD, and can be used to prevent medicines for controlling and/or treating and/or auxiliarily treating PTSD.

The present invention relates to compounds of formula I

wherein R¹, R², R³, R⁴, and R⁵ are as defined in the specification. Compounds of the invention are active on the GABAB receptor and are useful for treating a variety of CNS disorders, including anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity-and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastrointestinal disorders.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof,

• • (ii) a 5-HT_1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT_1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

This invention provides a method for treating depression and/or posttraumatic stress disorder in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.

The invention discloses a soldier wearable self-adaptation auxiliary treatment system based on artificial intelligence. A war simulating system, a physiological monitoring system and a self-adaption treatment system are set; battlefield simulation is carried out on a soldier through the war simulating system, the soldier can feel true scenes in a war, the physiological monitoring system monitors the physiological reaction generated when the soldier encounters the situation, and if data exception occurs, the self-adaption treatment system is adopted for carrying out relaxing treatment on the soldier; pictures which are not too irritative can be firstly presented during treatment, the horrifying degree of the pictures is gradually increased, and the soldier is made to accept various situations possibly happening on the battlefield step by step. The soldier wearable self-adaptation auxiliary treatment system can be suitable for soldier readaptation before the war and can also be suitablefor posttraumatic stress disorder of the soldier after the war, the treatment modes are flexible and diversified, the site simulation trueness is high, and the system has a good treatment effect on psychological counseling of the soldier before the war and posttraumatic stress disorder of the soldier after the war.

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

The present invention relates to compounds of formula

whereinX is —S— or —NH—;

• R³/R⁴ together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR₂, —CONR₂, —CO-lower alkyl or benzyl; or R³/R⁴ form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; and

R, R¹, R², and R⁵ are as defined herein and to pharmaceutically suitable acid addition salts thereof.

It has been found that the compounds of the invention are active on the GABA_B receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.

The invention discloses a deficiency-tonifying tranquilizing pill, and belongs to the technical field of Chinese patent medicines. The deficiency-tonifying tranquilizing pill comprises the traditional Chinese medicines according to the following components and formula: 4 parts of poria cocos, 5 parts of poria with hostwood, 3 parts of cassia twig, 2 parts of honey-fried licorice root, 2 parts of hangzhou white peony, 2 parts of dried ginger, 1 parts of keel, 1 parts of raw oysters, 1 parts of ophiopogon japonicas, 2 parts of polygala root, 2 parts of sun-dried ginseng, 4 parts of jujube and 1 part of saposhnikovia divaricata. The deficiency-tonifying tranquilizing pill provided by the invention has good control effects on body and mind responding symptoms caused by posttraumatic stress disorder, wherein the body and mind responding symptoms comprise spirit fatigue, strength lack, insomnia, irritability, too high vigilant intensity, muscular tension, excessive scare, dreaminess and the like.

The invention discloses application of an adenosine compound WS070133 shown as formula I in preparation of products for prevention or treatment of stress disorders. The stress disorders and related diseases include acute stress disorder, posttraumatic stress disorder, adjustment disorder and phobia, anxiety, mania, bipolar disorder and other diseases. Oral administration of WS070133 on posttraumatic stress disorder model animals shows that the adenosine compound has the effects of lowering animal stress level, reducing fear, anxiety like symptoms and learning and memory impairment. Study also shows that WS070133 can lower the corticosterone level and excitatory amino acid content, reduce apoptosis of neurons and has a regulation effect on related protein molecules. WS070133 has the advantages of low toxicity, no dependence, metabolic and addiction, quick metabolic clearance and no residual effect, etc., thus havaing good application and development prospects. (formula I).

Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

The invention discloses an application of doxycycline for preparing medicines for enhancing PAC1-R (Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor) dimer dependent constitutive activity. The doxycycline is used as a B type G-protein-coupled receptor PAC1-R dimmer for enhancing the PAC1-R dimer dependent constitutive activity so as to exert the biological functions through a PAC1-R mediated signal transduction pathway. As PAC1-R is a specific receptor of neuropeptide PACAP (Pituitary Adenylate Cyclase Activating Polypeptide), and PAC1-R mediates various important biological functions, so that the activity of the doxycycline to the PAC1-R dimer indicates that the doxycycline can be applied to treatment and medicinal development of diseases taking PAC1-R as target spots, for example, memory impairment, oligospermia, asthenozoospermia, posttraumatic stress disorder and the like.

The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide S receptor (NPSR), of the receptor TGR23 and/or of vasopressin receptor-related receptor 1 (VRR1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition. The invention also provides a method for identifying target neurons of a peptide in an animal, wherein the peptide is administered nasally.

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.

A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.

Provided is a method and apparatus for predicting a posttraumatic behavior problem that may predict a posttraumatic violent behavior problem of an individual, in detail, that may determine a biological phenotype of an individual experiencing a traumatic event within a predetermined period after the individual is exposed to the traumatic event, predict a violent symptom presentation probability of the individual based on the biological phenotype of the individual, and suggest an objective basis for preventive intervention in a development of posttraumatic stress disorder (PTSD) of the individual based on a prediction result.

The use of a phosphatase inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and/or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

Total glycosides of Cynanchum otophyllum Schneid can improve rats' chronic social frustration stress and chronic unpredictable mild stress model animal's symptoms, can improve high arousal behaviors of model animals' posttraumatic stress disorder in rats, and can be used in preparation of a medicine for treating and preventing chronic affective disorder and posttraumatic stress disorder.